REMS & RMP Support
A REMS (Risk Evaluation and Mitigation Strategy) or RMP (Risk Management Plan) is a critical safety program mandated by regulatory authorities to manage the risks associated with specific medications.
These programs ensure that patient access to necessary drugs while minimizing potential harm. REMS or RMP focuses on preventing, monitoring, and managing a specific serious risk by informing, educating, and reinforcing actions to reduce the likelihood and severity of adverse events. These programs reinforce safe medication use behaviors and educate stakeholders on essential precautions. ProPharma's Contact Center Operations support REMS and RMP programs by serving as a central point of contact for patients and healthcare providers. We offer a globally accessible REMS/RMP services in, over 40 languages, adapting to local working hours and days. Our offerings include scalability, flexibility, and customizable options to support an expanding REMS portfolio. By partnering closely with our clients, we share best practices driving both innovation and efficiency. We are committed to service advancements through the use of technologies such as workforce management tools, digital communication channels (including chatbots and live chat), customer satisfaction surveys after calls, and automated line testing.
Inquiry Support
- Global Availability: ProPharma operates globally, offering support in all supported languages and aligning with local time zones.
- Multi-Channel Platforms: Provides assistance across various regions through phone, chat, email and other communication channels.
- Expert Management: Handles specific inquiries from healthcare providers and patients regarding risk management and minimization measures.
- Informed Decision-Making: Facilitates informed decision-making for healthcare providers.
- Comprehensive Resources: Maintains a repository of response documents and a comprehensive database of all submitted inquiries.
- Regular Reporting: Ensures consistent and detailed reporting.
- Compliance and Cultural Sensitivity: Complies with local legislation and adheres to local customs and cultures.
Product Access and Information
- Critical Product Access Information: Provides essential information to ensure access to critical products.
- Efficient Dissemination: Streamlines the distribution of RMP materials, both electronically and in hard copy.
- Pharmacy and Program Locator: Help locate pharmacies and programs that support access to REMS-required medications for patients.
- Patient Support: We offer assistance to patients facing financial or access barriers.
Adverse Event (AE) Management
- Adverse Event Identification and Intake: Our experienced team efficiently identifies and intakes adverse events. Specific REMS questionnaire can be completed at intake.
- Rapid Response: Quickly Identify and respond to safety concerns notifying these immediately to the client.
- Accurate Triage: Ensure precise triage and effective communication with relevant teams.
- Expedited Reporting: Adheres to accelerated AE reporting timelines.
- Post-AE Follow-Up: Conducts thorough follow-up after adverse events in the local language either in writing or via telephone.
Training and Education
- Educational Material Provision: Distributes educational materials to patients, including brochures, guides, and alert cards.
- Up-to-Date Information: Keeps healthcare providers and patients informed on the latest risk management strategies and guidelines.
- Compliance Reminders: Provides reminders and information on best practices to ensure compliance.
- Certification Verification: Evaluates and verifies healthcare providers’ certification in REMS or RMP.
- Educational Session Support: Facilitates registration and follow-up for educational sessions.
Our REMS and RMP Experts
-
Valerie Huh
Director, Global Innovation and Implementation
View Bio
-
Ana Ming
Senior Global Innovation and Implementation Manager
View Bio
Valerie Huh
Valerie Huh brings over 20 years of experience in the pharmaceutical and healthcare industries, with expertise in global operations and process improvements. She holds a Doctor of Pharmacy (Pharm.D.), a degree in Chemistry, and an MBA with a certificate in business analytics. In her current role, she leads innovation and technology enablement in Medical Information and supports business expansions, driving forward strategic initiatives to enhance service quality and operational efficiency.
Ana Ming
Ana Ming is a highly skilled pharmacist based in Australia, with 12+ years of experience in the pharmaceutical services and healthcare industries. Currently at ProPharma, she brings expertise in medical information management, patient care, and regulatory compliance. Additionally, Ana is a certified Justice of the Peace (JP), combining her healthcare experience with a commitment to community service and ethical leadership. Her collaborative approach, coupled with a focus on innovative solutions, makes her a valuable asset in optimizing patient outcomes and advancing pharmaceutical practices.
REMS & RMP Contact Center Support
Ensure safe medication practices and minimize risks with ProPharma’s REMS/RMP support services. Our globally accessible solutions provide expert assistance to patients and healthcare providers in over 40 languages, enhancing risk management through informed decisions and reliable communication channels.
News & Insights
March 19, 2026
Operational Excellence in Global Clinical Research: Why Culture Drives Performan...
Discover why operational excellence in global clinical research hinges on culture, not just metrics. Learn how leadership, trust, and collaboration drive consistent quality outcomes.
March 17, 2026
Skinny Labels Under the Microscope: What Hikma v. Amarin Means for Drug Develope...
The Supreme Court's review of Hikma v. Amarin could reshape the legal and regulatory landscape for skinny labels and Section viii carve-outs.
January 27, 2026
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...
ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.
December 11, 2025
ProPharma Expands Operations with New Office in Hyderabad
ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.
January 31, 2025
ProPharma Recognized for AI Excellence at ECCCSA
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 9, 2024
ProPharma Receives 2024 CPHI Regulatory and Compliance Award
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
March 16, 2026
CMO Compass & Supply Chain Management
ProPharma provides comprehensive supply chain management and consulting services to support the efficient delivery of clinical trial materials throughout the product lifecycle. Using its CMO Compass®...
March 13, 2026
Restoring Inspection Readiness and Building a Long-Term Pharmacovigilance Partne...
A mid-sized biotechnology company operating in the EU faced critical pharmacovigilance (PV) compliance findings following an inspection by the European Medicines Agency and Medicines and Healthcare...
April 23, 2026
Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market
As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...
April 9, 2026
EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...
News & Insights
March 13, 2026
Restoring Inspection Readiness and Building a Long-Term Pharmacovigilance Partne...
A mid-sized biotechnology company operating in the EU faced critical pharmacovigilance (PV) compliance findings following an inspection by the European Medicines Agency and Medicines and Healthcare...
April 9, 2026
EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification
As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...